KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables (2017 - 2025)

Moderna (MRNA) has disclosed Receivables for 9 consecutive years, with $410.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables fell 1.68% to $410.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $410.0 million, a 1.68% decrease, with the full-year FY2025 number at $410.0 million, down 1.68% from a year prior.
  • Receivables was $410.0 million for Q4 2025 at Moderna, down from $1.0 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $3.2 billion in Q1 2022 to a low of $83.0 million in Q2 2025.
  • A 5-year average of $1.5 billion and a median of $1.3 billion in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: surged 43982.19% in 2021, then plummeted 90.01% in 2023.
  • Moderna's Receivables stood at $3.2 billion in 2021, then crashed by 54.84% to $1.4 billion in 2022, then crashed by 34.23% to $951.0 million in 2023, then crashed by 56.15% to $417.0 million in 2024, then dropped by 1.68% to $410.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Receivables are $410.0 million (Q4 2025), $1.0 billion (Q3 2025), and $83.0 million (Q2 2025).